

BOARD CHANGES

Resonance Health Ltd (ASX: RHT) (**Resonance Health** or **Company**) advises that Dr. Martin Blake has advised the Board of his intention to retire as Chair and Non-Executive Director of Resonance Health at the conclusion of the Company's Annual General Meeting (**AGM**) on 13 November 2025.

Mr. Aaron Brinkworth, who has been an Independent-Non-Executive Director of the Company since March 2023, will transition into the role of Chair of the Board following the AGM.

Having served as a director of the Company for over 18 years, Dr. Blake believes that now is the right time for an orderly succession of the role of Chair. Dr. Blake joined the Board in 2007 and has made a significant contribution to the development of Resonance Health during his years of service. During his tenure, the Company has expanded its portfolio of imaging analysis services, strengthened its financial and operational position, and established itself as a trusted provider of non-invasive medical imaging solutions worldwide.

Mr Brinkworth is an experienced biopharmaceutical executive having had a 22-year career with Gilead Sciences, Inc. (Nasdaq: GILD) (**Gilead**). During his tenure with Gilead the company grew from a small biotech-pharma enterprise into a multi-billion-dollar global organisation with annual sales exceeding USD \$27 billion. Mr Brinkworth's other current roles include that of Non-Executive Director of Proteomics International Laboratories Ltd (ASX: PIQ), Lixa Pty Ltd - a biotech company focused on antimicrobial resistance, and the Royal Lifesaving Society of Western Australia - a large not-for-profit organisation.

Incoming Chair, Mr. Aaron Brinkworth, commented:

"On behalf of all Resonance Health stakeholders, including my fellow directors, I thank Martin for his outstanding contribution to the Company since 2007. His steadfast stewardship has been integral to the Company's development over the past two decades and we wish him well and look forward to his continued involvement as shareholder of the Company."

In addition, the Company is pleased to announce that Mr. Andrew Harrison, the Company's CEO, has been elected a director of the Company and will assume the additional role, responsibility, and title of Managing Director.

Mr. Harrison has served as CEO of Resonance Health since July 2023, during which time the Company has advanced its portfolio of medical imaging solutions, broadened its global customer base, and strengthened its financial performance. Mr. Harrison led the acquisition of the TrialsWest business in 2024 and has overseen the award to Resonance Clinical of ~\$20 million in new clinical trial work. Mr. Harrison is also a major shareholder of the Company having purchased 8 million shares in 2023.

Mr. Harrison is an experienced CEO and Non-Executive Director of public listed and private companies across a range of industries, including radiology and medical AI. He founded and was Managing

Director of Capitol Health Ltd (ASX: CAJ) one of Australia's largest radiology companies, and he is experienced in capital markets, technology commercialisation, local and international M&A, and strategic restructuring and turnaround. He has substantial international experience including in US, European, and Chinese markets.

Resonance Health Chair, Dr Martin Blake, said:

“On behalf of the Board, I congratulate Andrew on his appointment as Managing Director and welcome him as a director. Andrew has demonstrated leadership, vision, and an unwavering commitment to the growth of Resonance Health. His focus and M&A execution capability have positioned the Company strongly for future success and this appointment is part of the Board’s broader strategy to align and strengthen governance as we pursue the next phase of growth. We look forward to the significant opportunities ahead.”

Mr Harrison’s key employment terms are enclosed at Annex A.

To watch Mr Harrison’s video discussion about the expansion, please visit the Company’s InvestorHub: <https://investors.resonancehealth.com/link/PBJVOP>

Further Information: <https://investors.resonancehealth.com>

Andrew Harrison – Chief Executive Officer

E: andrewh@resonancehealth.com

P: +61 (0)8 9286 5300

About Resonance Health

Resonance Health is an Australian healthcare technology and services company. The Company’s services are used globally by clinicians in the management of human diseases and by pharmaceutical and therapeutic companies in their clinical trials. Resonance Health has gained endorsement by leading physicians worldwide for providing high quality quantitative assessments essential in managing diseases and drug development.

Resonance Health’s dedication to scientific rigour and quality has enabled it to achieve regulatory clearances for a range of Software-as-Medical Devices (**SaMDs**) in the USA, Europe, UK, and Australia, and to proudly carry ISO 13485 certification for the design and manufacture of medical devices. Regulatory cleared SaMD products, some of which incorporate Artificial Intelligence (**AI**), include:

- **FerriScan**[®], a core-lab product that provides an accurate assessment of liver iron concentration (**LIC**) through non-invasive MRI-based technology, for use in the assessment of individuals with iron overload conditions. Internationally recognised as the gold standard in LIC assessment.
- **FerriSmart**[®], an AI-trained, non-invasive MRI-based device for the automated real-time assessment of LIC in patients, calibrated against the global gold standard, FerriScan[®].
- **HepaFatScan**[®], an MRI-based solution which provides a reliable non-invasive assessment of liver-fat in liver tissue for use in the assessment of individuals with confirmed or suspected fatty-liver-disease.
- **HepaFatSmart**[®], an AI-trained, non-invasive device for the automated real-time multi-metric assessment of liver-fat in patients, for the assessment of individuals with confirmed or suspected fatty liver disease.

- **LiverSmart®**, an AI-trained, non-invasive MRI-based multi-parametric device combining FerriSmart® and HepaFat-AI® into a consolidated report providing accurate assessment of LIC and liver fat.
- **CardiacT2***, the most widely accepted MRI method for assessing heart iron loading. Resonance Health offers a dual analysis of FerriScan® and CardiacT2*. CardiacT2* is TGA and CE Marking regulatory cleared.

The Company has a development pipeline of additional medical imaging analysis products and services, including the **MRI Liver Fibrosis Project**, aimed at accurately assessing the presence and progression of liver fibrosis utilising non-invasive MRI analysis.

The Company also operates Clinical Trial Management (CRO Services) and Clinical Trial Site (TrialsWest) businesses that cater to global clinical trial customers.

ANNEX A

Key terms of Mr. Harrison's employment:

- Fixed remuneration of \$433,880 p/a plus statutory superannuation.
- Annual short-term incentive (STIP) of up to 30% of fixed remuneration based on the achievement of key performance indicators (KPIs) aligned with shareholder interests, or payable in the event of a 'Change of Control' event.
- Annual long-term incentive (LTIP) of up to 30% of fixed remuneration, issued under the Company's ESOP (Incentive Awards Plan) *.
- Employment may be terminated by the Company or Mr. Harrison on 3-months' written notice.
- Upon termination of employment Mr Harrison will resign all positions and roles in any Group company.

** Following Mr Harrison's appointment as a director, future issuances of securities will be contingent on and subject to shareholder approval.*